Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

BioBlast® w/e 24 Jun 22: Alvotech dual NASDAQ listing, Samsung Bioepis/Samil ranibizumab, Formycon Q1/22 results, Daiichi Sankyo trastuzumab deruxtecan, Midas Pharma’s ranibizumab, Celltrion’s bevacizumab, Merck’s pembrolizumab, AVEO/Eli Lilly agreement, Innovent’s sintilimab

BioBlast® w/e 24 Jun 22: Alvotech dual NASDAQ listing, Samsung Bioepis/Samil ranibizumab, Formycon Q1/22 results, Daiichi Sankyo trastuzumab deruxtecan, Midas Pharma’s ranibizumab, Celltrion’s bevacizumab, Merck’s pembrolizumab, AVEO/Eli Lilly agreement, Innovent’s sintilimab

20 Jun 22 | CN | NMPA approves Innovent’s TYVYT® (sintilimab injection) Innovent Biologics and Eli Lilly announced that the CDE of China’s NMPA has approved the sNDA for TYVYT® (sintilimab injection) in combination...

read more
BioBlast® w/e 24 Jun 22: Alvotech dual NASDAQ listing, Samsung Bioepis/Samil ranibizumab, Formycon Q1/22 results, Daiichi Sankyo trastuzumab deruxtecan, Midas Pharma’s ranibizumab, Celltrion’s bevacizumab, Merck’s pembrolizumab, AVEO/Eli Lilly agreement, Innovent’s sintilimab

BioBlast® w/e 27 May 22 : Prestige’s trastuzumab rejected by CHMP; Additional EU indications for Merck’s Keytruda; Jury trial set in BMS/AstraZeneca patent infringement suit re durvalumab; First patients dosed in Biond Biologics trials for BND-22 (SAR444881); FDA approves Amneal’s Fylnetra™ (biosimilar pegfilgrastim).. and more

20 May 22 | EU | Prestige Biopharma (Roche/Genentech) | HD201, trastuzumab (Herceptin®) Prestige’s trastuzumab rejected by CHMP The CHMP recommended refusing the marketing authorisations for Prestige Biopharma’s...

read more
BioBlast® w/e 24 Jun 22: Alvotech dual NASDAQ listing, Samsung Bioepis/Samil ranibizumab, Formycon Q1/22 results, Daiichi Sankyo trastuzumab deruxtecan, Midas Pharma’s ranibizumab, Celltrion’s bevacizumab, Merck’s pembrolizumab, AVEO/Eli Lilly agreement, Innovent’s sintilimab

BioBlast® w/e 20 May 22

Alvotech’s biosim ustekinumab study results, Samsung Bioepis’ biosim ranibizumab approved in KR, Teva/BioEq’s biosim ranibizumab approved in the UK; Celltrion’s PhIII clinical trial for tocilizumab biosim

16 May 22 | Alvotech (Janssen) | AVT04, ustekinumab, (Stelara®)Alvotech announces study results for AVT04, biosimilar ustekinumab Alvotech announced positive top-line results from a 3 arm, parallel design study...

read more
Pearce IP practitioners prominent in WIPR Leaders 2022

Pearce IP practitioners prominent in WIPR Leaders 2022

Six practitioners ranked as AU patent/trade mark leaders

Pearce IP is proud to announce that 6 patent practitioners and 4 trade marks practitioners are ranked amongst the world’s best by WIPR Leaders 2022. Among the 47 patent experts ranked for Australia are 6 Pearce IP team...

read more
Three Pearce IP leaders ranked by MIP in 2022

Three Pearce IP leaders ranked by MIP in 2022

Two IP Stars & one Notable Practitioner

Pearce IP congratulates three of its patent leaders for being recognised by Managing IP (MIP) in its 2022 IP Stars ranking.  Two Pearce IP leaders Naomi Pearce and Jacinta Flattery-O’Brien PhD are again ranked by MIP...

read more
Psychedelic Medicines Part 1

Psychedelic Medicines Part 1

Patenting known and new chemical entities

Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately addressed by existing psychiatric or psychological therapies.  Despite the efforts of those seeking...

read more

Recent BioBlast® Updates

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.